Hargreaves, Sarah, Beasley, Matthew, Hurt, Chris ![]() ![]() |
![]() |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (578kB) |
Abstract
PATHOS is a phase II/III randomized controlled trial (RCT) of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery (TOS) for human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). The study opened in the UK in October 2015 and, after successful recruitment into the phase II, transitioned into phase III in the autumn of 2018. PATHOS aims to establish whether the de-intensification of adjuvant treatment in patients with favorable prognosis HPV-positive OPSCC will confer improved swallowing outcomes, whilst maintaining high rates of cure. In this article, we will outline the rationale for the study and how it aims to answer fundamentally important questions about the safety, effectiveness and functional outcomes of minimally invasive TOS techniques followed by adjuvant radiotherapy (RT) or chemo-radiotherapy (CRT) in this patient population.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine Centre for Trials Research (CNTRR) |
Publisher: | Frontiers Media |
ISSN: | 2234-943X |
Funders: | CRUK |
Date of First Compliant Deposit: | 24 October 2019 |
Date of Acceptance: | 6 September 2019 |
Last Modified: | 05 May 2023 14:46 |
URI: | https://orca.cardiff.ac.uk/id/eprint/126238 |
Citation Data
Cited 24 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |